SIRIS-Lab/unlabelled-sti-corpus huggingface dataset:
Patient specific biomimetic materials for bone regeneration

Over 2 million bone grafting procedures are performed annually worldwide nearly half of them in the EU, being the 2nd most transplanted tissue after blood. Bone defects pose a great clinical and socio-economic problem, only worsening with the ageing population. Even if bone harvested from the patient, bone banks or animals are common standard, they present serious disadvantages (limited availability, immune responses, disease transmission, ethical issues). Various synthetic bone grafts have been developed to minimize complications, yet with low success and failing to accelerate natural bone growth.
Bone3Dmatch revolutionizes the market of bone grafting (3.2bn€ globally) with a new generation of synthetic biomaterials. Two main disruptions are brought forward: 
1) Biomimicry: The biomaterial, its aqueous composition and low-temperature processing is capable of mimicking the bone creation conditions. Thus, it is recognised as natural bone by bone cells, accelerating the bone regeneration and the patient’s recovery. 
2) Patient customisation: Through advanced 3D printing technologies, it manufactures patient-specific scaffolds in less than 72h. This enables the treatment of complex bone defects, changing the current paradigm to a patient specific treatment. 
The company behind Bone3Dmatch is MIMETIS, a young SME built on the back of 25 years of research and business acumen in biomaterials for bone regeneration. Currently, MIMETIS offers biomimetic granules for the dental market. With an investment of 1.1M€, Bone3Dmatch will accelerate the market introduction of the 4th generation biomaterial in a completely new form (3D-printed scaffolds). Targeting orthopaedics and cranio-maxillofacial, we expect to reach the market in 2020 achieving 4,9M€ in revenues in only 3 years. Moreover, our ambition is to deploy a decentralised model where hospitals around the world are able to print their own patient-specific implants using our biomimetic biomaterial.
Innovoucher: implementing a european label for innovation vouchers

The main objective of INNOVOUCHER project is to develop a European Label for Innovation Voucher programmes, by defining a new model of innovation voucher programme supporting the transnational exchange of innovation services and the procedures of the award of the European Label to those programmes complying with the defined model.
The project will foster the transnational collaboration based in innovation vouchers by increasing the range of services offered in the vouchers scheme to include innovation transnational services and the definition of a procedure of automatic recognition of foreign providers, thus increasing the access of SMEs to knowledge and technology from all across Europe.
The project will define all the aspects of the model (vision, services catalogue, service providers, communication plan, voucher mechanism and the elements for the efficient management of the model), their minimum requirements to enable the European Label award and the European Label system, based on the experience of the consortium partners on the innovation vouchers management. The new model will be tested in real environment in a pilot project by the launch of an innovation voucher’s call in five regions to support only transnational exchange of innovation services.
Lessons learnt during the pilot project, jointly with the feedback from other regions from outside of the project will contribute to improve the defined model. The outcome of the project will consist on a guideline of recommendations on the European Label implementation that will provide the European Commission the tools, procedures and model of entity to manage a future European Label system. The guideline will be delivered in two phases: a first draft after the first year of the project and a reviewed version after the completion of the pilot project, at the third year. This guideline pretends to contribute the future policies to be developed by the European Commission on innovation support field.
Parenting practices during early childhood: validity evidence of a Brazilian scale

The present study aims to analyze the validity of evidence and internal consistency of an inventory for assessing parenting practices during early childhood.Participants were 857 mothers of one-to-42-months children recruited in three cities in the Southeast region and one city in the Midwest region of Brazil. The participants answered a sociodemographic questionnaire with maternal and child data, and the Parenting Styles Inventory for Mothers of Babies (IEPMB). The IEPMB includes 25 questions about positive and negative parenting practices that mothers use to raise their children. An exploratory and confirmatory factor analysis was conducted using the following criteria to indicate adequate model fit: root-mean-square error of approximation (RMSEA) < .08; standardized root mean square residual (SRMR) < .09; comparative fit index (CFI) > 0.90. For the hypothesis-testing method, a comparison between groups using a student's t-test based on the child's age (infants vs. toddlers) and mother's age (adolescents vs. adults) was carried out.The final 11 items model of the measure revealed an adequate overall model fit (RMSEA = 0.04; SRMR = 0.04; CFI = 0.94). The items were grouped into three constructs: Aggressiveness and Emotional Dysregulation, Relaxed Discipline, and Positive Monitoring. Adolescent mothers reported less positive monitoring than adult mothers (p < 0.001). Mothers of toddlers reported more aggressiveness/emotional dysregulation (p < 0.001) and relaxed discipline (p = 0.05) than mothers of infants.The instrument named from this study as the Parenting Practices Inventory for Mothers of Babies showed evidence for measuring mothers' parenting practices in early childhood and allows the identification of parents who need support.
Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic

It has been more than one year since the first case of the coronaviruses was infected by COVID-19 in China. The world witnessed three waves of the corona virus till now, and more upcoming is expected, whereas several challenges are presented. Empirical data displayed that the features of the virus effects do vary between the three periods. The severity of the disease, differences in symptoms, attitudes of the people have been reported, although the comparative characteristics of the three waves still keep essentially indefinite. In contrast, the sense of danger toward the cries gradually decreases in most countries. This may be due to some factors, including the approved vaccines, introducing alternative plans from politicians to control and deal with the epidemic, and decreasing the mortality rates. However, the alarm voice started to rise again with the appearance of new variant strains with several mutations in the virus. Several more questions began to be asked without sufficient answers. Mutations in COVID-19 have introduced an extreme challenge in preventing and treating SARS-COV-2. The essential feature for mutations is producing new variants known by high tensmibility, disturbing the viral fitness, and enhancing the virus replication. One of the variants that has emerged recently is the Delta variant (B.1.617.2), which was firstly detected in India. In November 2021, a more ferocious mutant appeared in South Africa, also called omicron (B.1.1.529). These mutants grabbed world attention because of their higher transmissibility than the progenitor variants and spread rapidly. Several information about the virus are still confusing and remains secret. There are eight approved vaccines in the market; however, the investigation race about their effect against reinfection and their role against the new variants is still under investigation. Furthermore, this is the first time vaccinating against COVID-19, so the question remains: Will we need an annual dose of the corona vaccines, and the side effects don't been observed till now?
Tribo-Electric-Nanogenerator for energy autonomous devices

Every day, we use products that have buttons, are moved around, and sit in the sunlight. We provide energy, but it’s wasted. Our company, Zolitron Technology, designs micro power supplies that charge themselves.  We RETROFIT existing products and design new products using these energy autonomous devices (EADs). With the EAD, we provide reliable energy for billions of potentially autonomous applications in home, industry, and medical use.  We’re removing batteries from wireless electronics.

Harvesting energy for powering devices is already a 1.1billion dollar market and expected to grow five times over the next six years.  Low power energy harvesting, in particular, has yet to be well integrated with existing electronics.

Our team has backgrounds in ultra-low power electronics from MIT and next generation solid state batteries from Harvard and RUB.

With this grant, we plan to hire an expert in Tribo-Electric-Nanogenerators (TENGs). TENGs harvest energy from friction, comparable to static electricity being generated when rubbing fur on an inflated balloon. Through carefully designed TENGs, most movement can be translated into friction and energy can be generated. Z.L. Wang from Georgiatech University published groundbreaking work on such generators, but other groups around the world build up on his research.

Since the TENGs require sophisticated energy management circuitry in the EAD, an electrical engineer, mechanical engineer or materials scientist is required to integrate TENGs into the EAD.
The role of microbial oxylipins in the microbe-host dialogue

OMIT aims to examine the role of microbial Oxylipins in the MIcrobiome:hosT dialogue. Oxylipins liberated from the oxidation of fatty acids are appreciated as key chemical signals perceived by both microbe and man. Human oxylipins (hOXY), comprising eicosanoids, docosanoids and octadecanoids are well characterised; they are implicit in many biochemical and signalling pathways in humans, including cell migration, proliferation, chemotaxis, immune reactions and most importantly, they are key regulators of inflammation. However, the diversity, functions, impact and mechanistic roles of microbially derived oxylipins (mOXY) are not well understood. State-of-the-art ultra-performance liquid chromatography-mass spectrometry (MS) platforms (secondment at Waters MS Headquarters, UK) will be developed and validated for oxylipin analysis in faecal samples and bacterial supernatants derived from co-incubation experiments (i.e. bacteria and oxlipin precursor). The latter will facilitate the discovery of novel mOXY. Additional bacterial biofilm assays will be performed to examine the role of mOXY in microbe-microbe interactions. To determine the contribution of mOXY in health and disease, biobanked samples from healthy volunteers and Crohns disease patients will be analysed. In vitro cell culture experiments and gene expression profiling will determine the function of mOXY in microbe-host interactions. During this project, the applicant will receive high quality training through research that will significantly improve scientific knowledge and provide a strong platform for building an independent research career. In line with the Work Programme for the MSCA fellowships, the knowledge and competencies gained by the applicant will add to developing her potential to achieve professional maturity and leadership in the field so that she may continue to make significant contributions to society and the economy.
Additional Sex Comb-like (ASXL) Proteins 1 and 2 Play Opposite Roles in Adipogenesis via Reciprocal Regulation of Peroxisome Proliferator-activated Receptor γ

Our previous studies have suggested that the mammalian additional sex comb-like 1 protein functions as a coactivator or repressor of retinoic acid receptors in a cell-specific manner. Here, we investigated the roles of additional sex comb-like 1 proteins in regulating peroxisome proliferator-activated receptors (PPARs). In pulldown assays in vitro and in immunoprecipitation assays in vivo, ASXL1 and its paralog, ASXL2, interacted with PPARα and PPARγ. In 3T3-L1 preadipocyte cells, overexpression of ASXL1 inhibited the induction of PPARγ activity by rosiglitazone, as shown by transcription assays, and completely suppressed adipogenesis, as shown by Oil Red O staining. In contrast, overexpression of ASXL2 greatly enhanced rosiglitazone-induced PPARγ activity and enhanced adipogenesis. Deletion of the heterochromatin protein 1 (HP1)-binding domain from ASXL1 caused the mutant protein to enhance adipogenesis similarly to ASXL2, indicating that HP1 binding is required for the adipogenesis-suppressing activity of ASXL1. Adipocyte differentiation was associated with a gradual decrease in ASXL1 expression but did not affect ASXL2 expression. Knockdown of ASXL1 and ASXL2 had reciprocal effects on adipogenesis. In chromatin immunoprecipitation assays in 3T3-L1 cells, ASXL1 occupied the promoter of the PPARγ target gene aP2 together with HP1α and Lys-9-methylated histone H3, whereas ASXL2 occupied the aP2 promoter together with histone-lysine N-methyltransferase MLL1 and Lys-9-acetylated and Lys-4-methylated H3 histones. Finally, microarray analysis demonstrated that ASXL1 represses, whereas ASXL2 increases, the expression of adipogenic genes, most of which are PPARγ targets. These results suggest that members of the additional sex comb-like family provide complex regulation of adipogenesis via differential modulation of PPARγ activity.
Active tectonics research using trenching technique on the south-eastern section of the Sudetic Marginal Fault (NE Bohemian Massif, central Europe)

Abstract The NW–SE striking Sudetic Marginal Fault (SMF) is one of the most conspicuous tectonic structures in central Europe. It controls the pronounced morphotectonic escarpment of the Sudetic Mountains for a length of 130 km. This paper presents the results of trenching on the SMF, undertaken in order to assess activity of the fault. The trenching technique has not hitherto been applied on either this particular fault system or elsewhere in the Bohemian Massif. However, it is the most effective tool for near-surface fault investigation in areas that are well vegetated and therefore devoid of fault outcrops. Moreover, the study area is situated in an intraplate region with a low displacement rate, which is exceeded by an erosion rate and does not favor the preservation of fault scarps. The trench sites were selected from prior DEM analyses, geomorphological fieldwork, and geophysical sounding. The trenches exposed a range of lithologies of Variscan crystalline rocks and Caenozoic sediments. At least four phases of faulting have been distinguished based on structural data, succession and age of the deformed sediments. Reverse faulting (N160°E), which displaced the Miocene sediments over the crystalline rocks, post-dates their deposition (15 Ma) and pre-dates Late Glacial gelifluction. Horizontal movements that have affected the Miocene deposits along a structure striking N35°E have the same wide time constraint. Younger reverse faulting, which caused a co-seismic relief step, post-dates the Late Glacial gelifluction but preceded the early Holocene colluvium deposition (10,940 ± 140 cal yrs BP). Normal faults striking N145°E, which cut the Miocene unit, might have been reactivated after the early Holocene colluvial sedimentation but before the buried soil (430 ± 120 cal yrs BP). Moreover, based on the identified prehistoric earthquake, respective minimum moment magnitude M 6.3 and slip rate 0.03 mm/year were estimated.
A unique technology in the world to identify and classify sounds from a home-based audition using intelligent algorithms to support remote diagnosis and monitoring of respiratory diseases.

Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The subject of the project is to conduct tests for the identification and classification of characteristics of the audible test signals and their collections, using advanced algorithms for detecting, comparing, integrating and learning, in order to support objective interpretation of the results of the audible examination conducted at home. The solution fits into the area of the telemedicine industry. The aim of the project is to create a system that will enable an audition to be carried out by a person without a medical education. As a result, the user will obtain information about recorded physiological and pathological sounds. It will also be able to send signals to the doctor and remotely consult the outcome. A separate pool of algorithms and possible filters associated with improving the quality and sharpening of emerging pathological sounds will be implemented for physicians to facilitate the auditory evaluation of the signals received. Detection algorithms will also be used to support the hearing process objectively, suggesting the possibility of pathology. The technology will be implemented in a product consisting of a measuring device and support software. The main purpose of the product is to diagnose children and people with chronic respiratory disorders. The Proof of Concept phase is planned to be completed by the start of the project. The aim of the project is to achieve readiness to implement and demonstrate technology in real conditions.
The isolation of online adjunct faculty and its impact on their performance

Using a grounded theory qualitative research approach, this article examines the experiences of 28 adjunct faculty members who work at the same university, exploring their views on whether periodically meeting face-to-face with management and peers has the potential to affect their motivation on the job and consequently the quality of education they provide to students. A few management representatives also shared their perspectives on the phenomenon; this enabled the researcher to compare the views of these two populations on whether face-to-face contact among faculty enhances teaching performance. The results of this study suggest a few issues that online schools must address in their efforts to improve adjuncts’ sense of affiliation and loyalty to their institution, which in turn will positively affect student retention levels. The main issues of concern to adjunct faculty are (a) inadequate frequency and depth of communication, regardless of the means used, whether online or face-to-face; (b) lack of recognition of instructors’ value to the institution; and (c) lack of opportunities for skill development.
Blocking inhibition of t-cell co-stimulation for anti-tumour therapy

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity.
Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed.
To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms.
To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution.
Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.
Precision medicine via diagnostic enzyme activity testing

PreMeDosE aims to ascertain the technical and commercial viability of a novel cytochrome P450 (CYP) enzyme activity assay, to enable truly personalised drug dosing for the first time. The CYP enzymes are responsible for the elimination of the majority of therapeutic drugs from the body. However, inter-individual variation in CYP activity leads to personal differences in drug elimination kinetics, both toxic accumulation (too slow elimination) and loss of therapeutic efficacy (too rapid elimination). The resulting adverse drug reactions have considerable clinical as well as economic consequences, accounting for ~5% of hospital admissions and increasing the mean stay from 8 to 20 days, and thereby affecting a patient’s quality of life and increasing healthcare costs. The inter-individual variation in elimination kinetics can have a genetic origin (some critical CYP enzymes are polymorphic), but substantial variations also arise from external factors, such as dietary agents, age, sex, disease state, and drug-drug interactions. Presently, only genetic variation can be measured but is not routinely recommended for clinical implementation because of the limited clinical utility. The PreMeDosE microfluidic assay permits for the first time measurement of the impacts of both genetic and external factors. The PreMeDosE assay permits direct measurement of CYP enzyme activity from a very small (biopsy-scale)  liver sample, providing personalized information of drug elimination kinetics and thus paving the way to customized drug dosing. PreMeDosE assay fits standard well plate technology so it is easily implemented in routine laboratory flow. Within this project, we will optimize and validate the PreMeDosE technology with the aim to ascertain its technical and commercial viability.